Biotechnology
Filter News
Found 46,710 articles
-
Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors
10/26/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announces the appointment of Mr. Tom Lindsay to its Board of Directors as an independent non-executive director.
-
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
10/26/2022
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the Independent Data Monitoring Committee (IDMC) for the randomised, controlled Phase IIb TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modifications.
-
Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference
10/26/2022
Cytek Biosciences, Inc., announced the company will be participating in the upcoming 31st Annual Credit Suisse Healthcare Conference in Rancho Palos Verdes, CA.
-
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
10/26/2022
CohBar, Inc. announced that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022.
-
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
10/26/2022
BioMarin Pharmaceutical Inc. announced financial results for the third quarter ended September 30, 2022.
-
Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation
10/26/2022
Applied Genetic Technologies Corporation and a newly established portfolio company of Syncona Limited, announced the commencement of the previously announced tender offer for all of the issued and outstanding shares of common stock of AGTC at a price of $0.34 per share in cash, at the closing of the transaction, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.
-
Biophytis Announces Receipt of Nasdaq Notice - October 26, 2022
10/26/2022
Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company's American Depositary Shares for the prior 30 consecutive business deay period, the Company no longer satisfies Nasdaq Listing Rule 5550.
-
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round
10/26/2022
ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently.
-
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
10/26/2022
Biogen Inc. announced new data from its industry-leading portfolio of multiple sclerosis therapies being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis meeting October 26-28, 2022.
-
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
10/26/2022
Biogen Inc. announced new data on multiple sclerosis disease measurement and advanced analytics being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis meeting October 26-28, 2022.
-
Kizoo invests in Rejuvenation Startup Mogling Bio
10/26/2022
Mogling Bio, a privately held biotech company, announces that it has successfully completed its first seed investment round.
-
Spruce Biosciences to Participate in November 2022 Investor Conferences
10/26/2022
Spruce Biosciences, Inc. announced that company management will participate in two upcoming investor conferences taking place in November.
-
Complete Genomics, part of MGI, Announces Next-Generation Sequencing Platforms at ASHG Annual Meeting
10/26/2022
Complete Genomics, part of MGI, celebrates the US commercial launch of their DNBSEQTM sequencing product line at the American Society of Human Genetics Annual Meeting, from October 25-29, in Los Angeles.
-
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
10/26/2022
Exelixis, Inc. announced promising initial results from the ongoing dose-escalation stage of JEWEL-101, a phase 1 study evaluating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate.
-
Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655
10/26/2022
Nuvalent, Inc. announced the presentation of new preclinical data for NVL-330, its recently nominated HER2-selective inhibitor, and NVL-655, its ALK-selective inhibitor currently under investigation in the ALKOVE-1 Phase 1/2 study for advanced ALK-positive non-small cell lung cancer and other solid tumors.
-
PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000
10/26/2022
PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio's celebrated HiFi sequencing technology.
-
PacBio Announces Onso, the Highly Accurate Short-Read Sequencing Platform
10/26/2022
PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the commencement of external beta testing of the Onso™ sequencing system.
-
PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15, 2022
10/26/2022
PacBio announced that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.
-
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
10/26/2022
Pieris Pharmaceuticals, Inc. today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.
-
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
10/26/2022
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR ("ENA") annual meeting to be held October 26-28, 2022.